Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marinomed Biotech AG Buyback Yield % Related Terms
Marinomed Biotech AG Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Marinomed Biotech AG's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:MARI vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Marinomed Biotech AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marinomed Biotech AG Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Marinomed Biotech AG's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinomed Biotech AG (WBO:MARI) has a Buyback Yield % of 0.00 as of Jul. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Marinomed Biotech AG and its competitors. According to the industry distribution chart, Marinomed Biotech AG ranks #999999 out of 740 companies in the Biotechnology industry.
Is Marinomed Biotech AG's Buyback Yield % too high?
Marinomed Biotech AG's current Buyback Yield % is 0.00. Based on the distribution chart, Marinomed Biotech AG ranks #999999 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #999999 out of 740 companies for Buyback Yield %. This places Marinomed Biotech AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Marinomed Biotech AG and its competitors. Marinomed Biotech AG's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.76, compared to a current price of €8.95 — trading 52.3% below its estimated fair value. The current Buyback Yield % is 0.00. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current Buyback Yield % is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?
Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued.
The current stock price of €8.95 is trading 52.3% below its estimated GF Value™ of €18.76.
GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.
Key valuation signals for WBO:MARI:
Buyback Yield %: 0.00
GF Value™: €18.76 vs. price of €8.95 (52.3% below fair value)
No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score
Get the complete analysis for WBO:MARI
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:MARI has been successfully added to your 
